Development of recombinant major capsid protein Vaccine and assessment of its efficacy against SRDV in similar damselfish (Pomacentrus similis)

Viral vaccines against emerging viral diseases are crucial for encouraging successful aquaculture production. In this research, an experimental recombinant major capsid protein vaccine of similar damselfish virus was prepared and examined for its efficacy in marine ornamental fish, similar damselfish (Pomacentrus similis). The MCP gene of the SRDV was amplified from the viral DNA by a specific primer set viz bamHI and XhoI- restriction sites and confirmed by agarose gel electrophoresis with a target size of 1416 bp. The gel-purified PCR product was double-digested with the said enzymes and incorporated into the pTriEx1.1 vector, which was subsequently transformed to E. coli DH5 alpha. The plasmids of the two clones pTriEx-MCP-1416-1 and pTriEx-MCP-1416-3 were transformed to E. coli BL21 (DE-3) pLacI. A crude protein compound derived from a colony of E. coli BL21 (DE-3) with expressed MCP inserts was used to evaluate efficacy in similar damselfish by intra-peritoneal injection. After the challenge with SRDV, damselfish vaccinated with recombinant protein showed a lower protection level, while the fish vaccinated with recombinant protein supplemented Quil-A (R) adjuvant showed an RPS of 26%. According to RPS values recorded from the vaccinated and non-vaccinated damselfish group, the recombinant protein vaccine conferred only marginal protection against the SRDV challenge.

Automated summary

An experimental recombinant major capsid protein vaccine was developed and tested for its efficacy in marine ornamental fish. The results showed that the vaccine provided only marginal protection against the targeted virus.